Drug utilisation registry for Teflaro (ceftaroline fosamil)

Trial Profile

Drug utilisation registry for Teflaro (ceftaroline fosamil)

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 May 2017

At a glance

  • Drugs Ceftaroline fosamil (Primary)
  • Indications Bacteraemia; Community-acquired pneumonia; Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia; Osteomyelitis; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Acronyms CAPTURE
  • Sponsors Cerexa
  • Most Recent Events

    • 31 May 2017 According to an Allergan media release, data from this study will be presented at at the upcoming American Society for Microbiology (ASM) 2017.
    • 30 Oct 2016 Results (n=85) assessing the effect of ceftaroline fosamil in hospital acquired pneumonia and ventilator associated pneumonia patients, presented at the IDWeek 2016
    • 30 Oct 2016 Results assessing effect of ceftaroline fosamil in patients with Gram-positive bacteremia (n=252) presented at the IDWeek 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top